Description

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Metabolism-sugar/lipid metabolism–C184H282N50O60S—Acta Biochim Biophys Sin (Shanghai). 2017 Jul 1;49(7):573-580.|Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1019-E1030.|Annals of the Romanian Society for Cell Biology. 2021 Mar 15.|Asian J Pharm Sci. 2024 Mar 12, 100904.|Biochim Biophys Acta Mol Cell Res. 2022 May 27;1869(9):119300.|Biomedicines. 2020 Nov 9;8(11):485.|bioRxiv. 2020 Jul.|bioRxiv. 2024 Mar 20.|BMC Biol. 2021 Mar 3;19(1):40.|Br J Pharmacol. 2020 Aug;177(15):3389-3402. |Chem Biol Interact. 2019 May 1;304:186-193.|Drug Deliv. 2022 Dec;29(1):548-560.|Exp Cell Res. 2023 Jan 7;113469.|Front Behav Neurosci. 05 January 2022.|Front Pharmacol. 2019 Oct 25;10:1230.|Front Pharmacol. 2021 Jul 19;12:694476.|Gerontology. 2023 Mar 7;1-12.|Gut. 2022 Jun 13;gutjnl-2021-326541.|Int Immunopharmacol. 2021 Jan;90:107192.|Int Immunopharmacol. 2023 May 19;120:110339.|Int J Biol Sci. 2022; 18(4): 1328-1346.|J Biol Chem. 2018 Nov 23;293(47):18086-18098. |J Cell Physiol. 2021 May;236(5):3641-3659.|J Diabetes Res. 2019 Dec 9;2019:8905917.|J Funct Foods. 2023 Aug, 107, 105706.|J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1.|J Neuroinflammation. 2019 Nov 28;16(1):242.|Mol Metab. 2023 Sep 26, 101811.|Neural Regen Res. 2022.|Neurogastroenterol Motil. 2019 Feb;31(2):e13482.|Sci Rep. 2017 Jun 28;7(1):4351.|SSRN. 2019 Jun 27.|Structure. 2022 Feb 2;S0969-2126(22)00006-5.|Biomaterials. 2021 Aug;275:120944.-[1]Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114(2-3):153-8.|[2]Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E947-57.|[3]Fidan-YaylalI G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016 Feb;37(2):2647-53.|[4]Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. Hepatology. 2006 Jan;43(1):173-81.|[5]Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010 Jan;53(1):153-9.|[6]Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol. 2014 Apr 2;13:69.–141758-74-9–4186.57–99.94–O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N5[C@@H](CCC5)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N6[C@@H](CCC6)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC9=CNC=N9)N–Metabolic Disease–DMSO : ≥ 32 mg/mL|Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 33.33 mg/mL (ultrasonic)–GCGR—-GPCR/G Protein–Peptides